FDA approval
Colin Kerr
Published: Wednesday, May 1, 2019
Aerie Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has approved Rocklatan™ to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
“Rocklatan is a once-daily eye drop that is a fixed-dose combination of latanoprost and netarsudil, the active ingredient in Rhopressa® (netarsudil ophthalmic solution) 0.02%, a Rho kinase (ROCK) inhibitor specifically designed to target the trabecular meshwork. Rhopressa works by restoring outflow through the trabecular meshwork, while latanoprost increases fluid outflow through the uveoscleral pathway,” said a company spokesman.
www.aeriepharma.com
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.